June 20, 2018
CDMO Outlook: Preparing for the Next Opportunity
By: Jim Miller, founder and former president of PharmSource, now part of GlobalData.

Demand for capacity has driven the market for contract development and manufacturing (CDMO) services, but capacity alone will not be enough in the near term as CDMOs need to look to differentiate their offerings.
 
CDMO strategies need to look beyond today’s opportunities and brace for changing market conditions and avoid the price competition that will come as supply and demand for capacity come into balance.
Mid-Year Review: The Top 10 Deals of 2018
By: Patricia Van Arnum, DCAT Editorial Director

So which mergers and acquisitions among pharmaceutical companies have made the mark thus far in 2018?  DCAT Value Chain Insights  takes an inside look.

Two $60-billlion deals top the list. First is Bayer’s $63-billion acquisition of Monsanto, an agrochemical and seed company, the largest deal in Bayer’s history and a move to fortify its strategy of being a pure-play life-sciences company. The second is Takeda’s proposed $62-billion acquisition of Shire, coming just two years after Shire’s $32-billion acquisition of Baxalta, the biopharmaceutical company spun off from Baxter Healthcare. What other deals of import have been made thus far in 2018?
VCI Headliners: Top Industry News
The VCI Debrief: PHARMA NEWS
The VCI Debrief: SUPPLIER NEWS
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of Pharmaceutical Technology from 2006 to 2014 and Executive Editor of ICIS Chemical Business and Chemical Market Reporter ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .